Compare Advanced Cell Diagnostics vs Focus Diagnostics
Customers evaluate the quality of Advanced Cell Diagnostics's products using the following success metrics.
Overview
Advanced Cell Diagnostics is based in United States
Advanced Cell Diagnostics (ACD) is a provider in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope(TM) technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.
Focus Diagnostics is 46 yrs old and is based in United States.
Focus Diagnostics develops diagnostic and database services and products for infectious and immunological diseases. On July 14th, 2006, Focus Diagnostics was acquired by Quest Diagnostics.
Demo Video
Leadership
Jessie Qian Wang (Chief Financial Officer)
Laurence R. McCarthy (Chief Technology Officer)
Investors
Bio-Techne, Morningside Ventures
Quest Diagnostics and Sprout Group
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Advanced Cell Diagnostics has not claimed their profile.
Work for Advanced Cell Diagnostics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Advanced Cell Diagnostics?
Claim your profile now.
Information not available because Focus Diagnostics has not claimed their profile.
Work for Focus Diagnostics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Focus Diagnostics?
Claim your profile now.